Fondaparinux: Synthetic pentasaccharide that mediates the interaction of HEPARIN with ANTITHROMBINS and inhibits FACTOR Xa; it is used for prevention of VENOUS THROMBOEMBOLISM after surgery. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
fondaparinux : A synthetic pentasaccharide which, apart from the O-methyl group at the reducing end of the molecule, consists of monomeric sugar units which are identical to a sequence of five monomeric sugar units that can be isolated after either chemical or enzymatic cleavage of the polymeric glycosaminoglycans heparin and heparan sulfate. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 5282448 |
| CHEMBL ID | 1201202 |
| CHEBI ID | 61033 |
| SCHEMBL ID | 17655218 |
| MeSH ID | M0403648 |
| Synonym |
|---|
| CHEBI:61033 , |
| CHEMBL1201202 |
| methyl 2-deoxy-6-o-sulfo-2-(sulfoamino)-alpha-d-glucopyranosyl-(1->4)-beta-d-glucopyranuronosyl-(1->4)-2-deoxy-3,6-di-o-sulfo-2-(sulfoamino)-alpha-d-glucopyranosyl-(1->4)-2-o-sulfo-alpha-l-idopyranuronosyl-(1->4)-2-deoxy-6-o-sulfo-2-(sulfoamino)-alpha-d-g |
| 104993-28-4 |
| trisulfoamino heparin pentasaccharide |
| sr 90107 |
| alpha-d-glucopyranoside, methyl o-2-deoxy-6-o-sulfo-2-(sulfoamino)-alpha-d-glucopyranosyl-(1-4)-o-beta-d-glucopyranuronosyl-(1-4)-o-2-deoxy-3,6-di-o-sulfo-2-(sulfoamino)-alpha-d-glucopyranosyl-(1-4)-o-2-o-sulfo-alpha-l-idopyranuronosyl-(1-4)-2-deoxy-2-(su |
| DB00569 |
| natural heparin pentasaccharide |
| fondaparinux |
| hsdb 7845 |
| j177fow5jl , |
| unii-j177fow5jl |
| fondaparinux [vandf] |
| fondaparinux [who-dd] |
| fondaparinux [hsdb] |
| gtpl6819 |
| fondaparin |
| DTXSID10146903 , |
| SCHEMBL17655218 |
| Q27077698 |
| bdbm50511579 |
| a-d-glucopyranoside, methylo-2-deoxy-6-o-sulfo-2-(sulfoamino)-a-d-glucopyranosyl-(14)-o-b-d-glucopyranuronosyl-(14)-o-2-deoxy-3,6-di-o-sulfo-2-(sulfoamino)-a-d-glucopyranosyl-(14)-o-2-o-sulfo-a-l-idopyranuronosyl-(14)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen |
| (2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-6-[(2r,3s,4s,5r,6r)-2-carboxy-4-hydroxy-6-[(2r,3s,4r,5r,6s)-4-hydroxy-6-methoxy-5-(sulfoamino)-2-(sulfooxymethyl)oxan-3-yl]oxy-5-sulfooxyoxan-3-yl]oxy-5-(sulfoamino)-4-sulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxy-3-[(2r,3r |
| EN300-19769274 |
| methyl-o-2-deoxy-6-o-sulfo-2-(sulfoamino)-alpha-d-glucopyranosyl-(1-->4)-o-beta-d-glucopyra-nuronosyl-(1-->4)-o-2-deoxy-3,6-di-o-sulfo-2-(sulfoamino)-alpha-d-glucopyranosyl-(1-->4)-o-2-o-sulfo-alpha-l-idopyranuronosyl-(1-->4)-2-deoxy-6-o-sulfo-2-(sulfoami |
| dtxcid9069394 |
Fondaparinux sodium is a novel antithrombotic agent, the first of a new class of selective factor Xa inhibitors. It is approved for the prevention and treatment of venous thromboembolic events, that is, deep vein thrombosis, pulmonary embolism, and superficial veins.
Fondaparinux has a favorable tolerability profile, particularly with regard to the risk of major bleeding, and limited data suggest that it is more cost effective than enoxaparin in the short term. The drug has a linear pharmacokinetic profile allowing once-daily subcutaneous administration.
Fondaparinux has been evaluated in a large population of patients presenting with a SVT. It has a favorable tolerability profile, particularly with regard to the risk of major bleeding, and limited data suggest it is more cost effective than enoxaparin.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Fondaparinux has a diminished risk of HIT." | ( [From heparin to apixaban: anticoagulants cut both ways?]. Bock, F; Hartung, K; Isermann, B; Meyer, F, 2014) | 1.12 |
| "Fondaparinux has an increased bleeding risk in patients with a CrCl ≤ 50 mL/min and is contraindicated if CrCl < 30 mL/min. " | ( Clinical experience with prophylactic fondaparinux in critically ill patients with moderate to severe renal impairment or renal failure requiring renal replacement therapy. An, G; Antigua, A; Bushwitz, J; Cope, J; Patel, A; Zumberg, M, 2015) | 2.13 |
| "Fondaparinux has a favorable tolerability profile, particularly with regard to the risk of major bleeding, and limited data suggest that it is more cost effective than enoxaparin in the short term." | ( Spotlight on fondaparinux sodium in acute coronary syndromes. Blick, SK; Orman, JS; Scott, LJ; Wagstaff, AJ, 2008) | 1.44 |
| "Fondaparinux has a low allergenic potential. " | ( Low allergenic potential with fondaparinux: results of a prospective investigation. Boehncke, WH; Garbaraviciene, J; Hecking, C; Kaufmann, R; Kroll, H; Lindhoff-Last, E; Ludwig, RJ; Marzi, I; Scheuermann, J; Schindewolf, M; Wolter, M, 2010) | 2.09 |
| "Fondaparinux has a favourable efficacy-safety profile but if major bleeding occurs, reversal of antithrombotic treatment is challenging. " | ( Use of recombinant factor VIIa (NovoSeven(®)) in 8 patients with ongoing life-threatening bleeding treated with fondaparinux. Bernard, Y; Briand, F; Chopard, R; Descotes-Genon, V; Ecarnot, F; Guignier, A; Janin, S; Luporsi, P; Meneveau, N; Racadot, E; Schiele, F; Séronde, MF, 2011) | 2.02 |
| "Fondaparinux has a highly favorable pharmacokinetic profile; four large phase 3 trials comparing subcutaneous fondaparinux 2.5 mg once daily with the low molecular weight heparin (LMWH) enoxaparin in doses approved by regulatory bodies showed that fondaparinux reduced the overall risk of VTE in major orthopedic surgery by > 50% without increasing clinically relevant bleeding." | ( Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism. Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2002) | 1.04 |
| "Fondaparinux has a linear pharmacokinetic profile allowing once-daily subcutaneous administration." | ( Fondaparinux, the first selective factor Xa inhibitor. Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2003) | 2.48 |
| "Fondaparinux has a half-life compatible with once-a-day administration; modification of its structure (idraparinux) has led to more stable binding with antithrombin and to an increase in its half-life to allow once-a-week administration." | ( New trends in anticoagulant therapy. Iliceto, S; Pegoraro, C; Pengo, V, 2004) | 1.04 |
| "Fondaparinux has a favorable tolerability profile, particularly with regard to the risk of major bleeding, and limited data suggest that it is more cost effective than enoxaparin in the short term." | ( Fondaparinux sodium: a review of its use in the management of acute coronary syndromes. Blick, SK; Orman, JS; Scott, LJ; Wagstaff, AJ, 2008) | 2.51 |
| "Fondaparinux has been also successfully used in HIT." | ( Heparin-induced thrombocytopenia treated with fondaparinux: single center experience. Dulicek, P; Fiedlerova, Z; Hirmerova, J; Ivanova, E; Kostal, M; Sadilek, P, 2020) | 1.54 |
| "Fondaparinux has been identified as a useful alternative in such patients; here we present the first two documented cases in Australia and a literature review." | ( Non-immediate heparin and heparinoid cutaneous allergic reactions: a role for fondaparinux. Ekstrom, C; Lucas, M; Tan, E; Thompson, G, 2018) | 1.43 |
| "Fondaparinux has been shown to be superior to low molecular weight heparin in preventing deep vein thrombosis." | ( The clinical use of Fondaparinux: A synthetic heparin pentasaccharide. Pan, N; Tan, L; Zhang, L; Zhang, M; Zhang, Y, 2019) | 1.56 |
| "Fondaparinux has a diminished risk of HIT." | ( [From heparin to apixaban: anticoagulants cut both ways?]. Bock, F; Hartung, K; Isermann, B; Meyer, F, 2014) | 1.12 |
| "Fondaparinux has an increased bleeding risk in patients with a CrCl ≤ 50 mL/min and is contraindicated if CrCl < 30 mL/min. " | ( Clinical experience with prophylactic fondaparinux in critically ill patients with moderate to severe renal impairment or renal failure requiring renal replacement therapy. An, G; Antigua, A; Bushwitz, J; Cope, J; Patel, A; Zumberg, M, 2015) | 2.13 |
| "Fondaparinux has similar effectiveness and safety as argatroban and danaparoid in patients with suspected HIT." | ( Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study. Alahmadi, M; Kang, M; Kovacs, MJ; Lazo-Langner, A; Sawh, S, 2015) | 2.58 |
| "Fondaparinux has been administered alone at 2·5 mg subcutaneously once daily for 24 days during the interruption of warfarin perioperatively." | ( Prolonged use of fondaparinux for perioperative bridging: a case report of a patient with mechanical heart valve and heparin-induced thrombocytopenia. Li, DM; Song, XJ; Wang, CT; Wei, M, 2015) | 1.48 |
| "Fondaparinux has been evaluated in a large population of patients presenting with a SVT." | ( The safety of fondaparinux sodium for the treatment of venous thromboembolism. Dentali, F; Mastroiacovo, D; Sala, G, 2016) | 1.52 |
| "Fondaparinux has excellent bioavailability when administered subcutaneously, has a longer half-life than LMWHs, and is given once daily by subcutaneous injection in fixed doses, without anticoagulant monitoring." | ( Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Bauer, KA; Donati, MB; Gould, M; Hirsh, J; Samama, MM; Weitz, JI, 2008) | 1.07 |
| "Fondaparinux has a favorable tolerability profile, particularly with regard to the risk of major bleeding, and limited data suggest that it is more cost effective than enoxaparin in the short term." | ( Spotlight on fondaparinux sodium in acute coronary syndromes. Blick, SK; Orman, JS; Scott, LJ; Wagstaff, AJ, 2008) | 1.44 |
| "Fondaparinux has proven its safety by patients over 100 kg." | ( Severe bleeding secondary to misuse of fondaparinux: a case report. Bohand, X; Bousquet, A; Le Garlantezec, P; Nielly, H; Perrier, E, 2010) | 1.35 |
| "Fondaparinux has been shown to reduce the risk of major bleeding and 30-day mortality compared with enoxaparin, in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS). " | ( Cost effectiveness of fondaparinux in non-ST-elevation acute coronary syndrome. de-Miguel-Balsa, E; Latour-Perez, J, 2009) | 2.11 |
| "Fondaparinux has been used in a small number of patients with HIT and generally appears to be safe." | ( Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation. Ortel, TL, 2009) | 1.07 |
| "Fondaparinux has recently been approved in patients with acute coronary syndromes. " | ( Routine use of fondaparinux in acute coronary syndromes: a 2-year multicenter experience. Bassand, JP; Chopard, R; Descotes-Genon, V; Dutheil, J; Ecarnot, F; Meneveau, N; Schiele, F; Seronde, MF, 2010) | 2.16 |
| "Fondaparinux has minimal affinity for platelet factor 4, making it an alternative agent to unfractionated heparin (UFH) and low-molecular weight heparin (LMWH) and a plausible consideration for patients with a history of HIT." | ( Successful use of fondaparinux in a patient with a mechanical heart valve replacement and a history of heparin-induced thrombocytopenia. Corbett, TL; Elher, KS; Garwood, CL, 2010) | 1.42 |
| "Fondaparinux has a low allergenic potential. " | ( Low allergenic potential with fondaparinux: results of a prospective investigation. Boehncke, WH; Garbaraviciene, J; Hecking, C; Kaufmann, R; Kroll, H; Lindhoff-Last, E; Ludwig, RJ; Marzi, I; Scheuermann, J; Schindewolf, M; Wolter, M, 2010) | 2.09 |
| "Fondaparinux has a favourable efficacy-safety profile but if major bleeding occurs, reversal of antithrombotic treatment is challenging. " | ( Use of recombinant factor VIIa (NovoSeven(®)) in 8 patients with ongoing life-threatening bleeding treated with fondaparinux. Bernard, Y; Briand, F; Chopard, R; Descotes-Genon, V; Ecarnot, F; Guignier, A; Janin, S; Luporsi, P; Meneveau, N; Racadot, E; Schiele, F; Séronde, MF, 2011) | 2.02 |
| "Fondaparinux (FPX) has been used to treat and prevent DVT, however interindividual difference of the drug efficacy exists." | ( [Risk factor for residual deep vein thrombosis after fondaparinux administration in patients with postoperative replacement arthroplasty]. Enokiya, T; Hasegawa, M; Iwamoto, T; Kawase, R; Muraki, Y; Okuda, M; Sudo, A; Uchida, A, 2012) | 1.35 |
| "Fondaparinux has demonstrated equivalence to enoxaparin in reducing cardiovascular events, but with a lower rate of bleeding in patients using fondaparinux." | ( Cost-effectiveness of fondaparinux in patients with acute coronary syndrome without ST-segment elevation. Machado, M; Olimpio, A; Pepe, C; Ramos, R, 2012) | 1.41 |
| "Fondaparinux sodium has not been reported to cause antibody-induced thrombocytopenia." | ( Fondaparinux sodium. Goa, KL; Keam, SJ, 2002) | 2.48 |
| "Fondaparinux has a highly favorable pharmacokinetic profile; four large phase 3 trials comparing subcutaneous fondaparinux 2.5 mg once daily with the low molecular weight heparin (LMWH) enoxaparin in doses approved by regulatory bodies showed that fondaparinux reduced the overall risk of VTE in major orthopedic surgery by > 50% without increasing clinically relevant bleeding." | ( Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism. Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2002) | 1.04 |
| "Fondaparinux has shown efficacy in the prevention of venous thromboembolism in patients undergoing hip or knee replacement surgery. " | ( Fondaparinux: a new antithrombotic agent. Cheng, JW, 2002) | 3.2 |
| "Fondaparinux has no effect on coagulation tests and does not bind to platelet factor 4 or promote heparin-induced thrombocytopenia." | ( Fondaparinux sodium. Reverter, JC, 2002) | 2.48 |
| "Fondaparinux has demonstrated its efficacy compared to a widely used low-molecular-weight heparin in a number of thromboprophylaxis trials after major orthopedic surgery and is approved for use in this setting." | ( A new antithrombotic strategy, the selective inhibition of coagulation factors, and its importance to the orthopedic specialist. Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2002) | 1.04 |
| "Fondaparinux has nearly complete bioavailability after subcutaneous injection." | ( Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Gerotziafas, GT; Samama, MM, 2003) | 1.26 |
| "Fondaparinux has a linear pharmacokinetic profile allowing once-daily subcutaneous administration." | ( Fondaparinux, the first selective factor Xa inhibitor. Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2003) | 2.48 |
| "Fondaparinux has been approved for use in thromboprophylaxis after major orthopedic surgery, where it has demonstrated its efficacy compared to a low-molecular-weight heparin." | ( New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology. Bauer, KA, 2003) | 1.04 |
| "Fondaparinux has been recently approved for use in thromboprophylaxis after major orthopedic surgery." | ( New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies. Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2003) | 1.04 |
| "Fondaparinux has been extensively investigated in two areas: orthopedic surgery and venous thromboembolism." | ( Pentasaccharides in the prophylaxis and treatment of venous thromboembolism: a systematic review. Huisman, MV; Nijkeuter, M, 2004) | 1.04 |
| "Fondaparinux has a half-life compatible with once-a-day administration; modification of its structure (idraparinux) has led to more stable binding with antithrombin and to an increase in its half-life to allow once-a-week administration." | ( New trends in anticoagulant therapy. Iliceto, S; Pegoraro, C; Pengo, V, 2004) | 1.04 |
| "Fondaparinux currently has licenses in the UK for thromboprophylaxis and treatment of VTE and a license for the management of acute coronary syndrome is likely to be forthcoming." | ( Anticoagulation via anti-Factor Xa inhibition. Hunt, BJ; Wiles, N, 2006) | 1.06 |
| "Fondaparinux has the approval for its introduction into the market as a maximum representative of this group and has begun to be used." | ( [Deep vein thrombosis: new drugs and future therapeutic perspectives]. Berga Fauria, C; García Vidal, R; Paredero, VM, 2006) | 1.06 |
| "Fondaparinux has a favorable tolerability profile, particularly with regard to the risk of major bleeding, and limited data suggest that it is more cost effective than enoxaparin in the short term." | ( Fondaparinux sodium: a review of its use in the management of acute coronary syndromes. Blick, SK; Orman, JS; Scott, LJ; Wagstaff, AJ, 2008) | 2.51 |
| "Fondaparinux has not shown any impairment in vitro." | ( The effect of anticoagulant pharmacotherapy on fracture healing. Cockbain, AJ; El Masry, MA; Katonis, P; Lindner, T; Schizas, C; Tsiridis, E, 2008) | 1.07 |
| "Fondaparinux has been shown to be as effective as enoxaparin in the prevention of thrombosis in patients undergoing orthopedic surgery and showed similar results compared to enoxaparin or UFH in patients with deep-vein-thrombosis or pulmonary embolism." | ( Factor Xa inactivation in acute coronary syndrome. Barantke, M; Bonnemeier, H, 2008) | 1.07 |
Fondaparinux does not inhibit thrombin activity, release tissue factor pathway inhibitor, or possess other properties of heparin such as anti-inflammatory, anti-viral, and anti-angiogenesis.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Fondaparinux does not inhibit thrombin activity, release tissue factor pathway inhibitor, or possess other properties of heparin such as anti-inflammatory, anti-viral, anti-angiogenesis, anti-neoplastic, and anti-metastatic effects though high affinity interactions with a variety of proteases, protease inhibitors, chemokines, cytokines, growth factors, and their respective receptors." | ( The clinical use of Fondaparinux: A synthetic heparin pentasaccharide. Pan, N; Tan, L; Zhang, L; Zhang, M; Zhang, Y, 2019) | 1.56 |
| "Fondaparinux did not inhibit osteoblast proliferation in vitro and may reduce the risk of heparin-induced osteoporosis associated with long-term heparin administration." | ( Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. Handschin, AE; Hoerstrup, SP; Kock, HJ; Trentz, O; Trentz, OA; Wanner, GA, 2005) | 2.02 |
Fondaparinux treatment decreased the thickness of submesothelial fibrotic tissue, and size and number of CD31-positive vessels. Treatment with fondaparinUX resulted in less cost and more AEs averted, hence dominating argatroban.
Fondaparinux is attributable to fewer adverse events and similar pregnancy outcomes compared with LMWH in patients with recurrent miscarriage. Enoxaparin was found to be as safe as aspirin with respect to bleeding.
The favourable pharmacokinetic profile of fondaparinux sodium is likely to play an important role in the major advance that the drug represents in the prevention and treatment of thrombotic disorders.
| Excerpt | Reference | Relevance |
|---|---|---|
| "9 ml/min, and the terminal half-life was 17 hours in young volunteers and 21 hours in elderly volunteers." | ( The pharmacokinetics of fondaparinux sodium in healthy volunteers. Cariou, R; de Greef, R; Donat, F; Duret, JP; Magnani, H; Necciari, J; Santoni, A, 2002) | 0.62 |
| "The favourable pharmacokinetic profile of fondaparinux sodium is likely to play an important role in the major advance that the drug represents in the prevention and treatment of thrombotic disorders." | ( The pharmacokinetics of fondaparinux sodium in healthy volunteers. Cariou, R; de Greef, R; Donat, F; Duret, JP; Magnani, H; Necciari, J; Santoni, A, 2002) | 0.89 |
| " Pharmacokinetic simulations were performed using a population pharmacokinetic model based on data obtained in 756 patients undergoing major orthopedic surgery." | ( Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients. Boyle, DA; Fuji, T; Lensing, AW; Turpie, AG, 2009) | 0.6 |
| " A population pharmacokinetic model of fondaparinux, based on data obtained in patients included in phase II/III trials, has been described." | ( Population pharmacokinetics of fondaparinux administered at prophylactic doses after major orthopaedic surgery in everyday practice. Baylot, D; Borg, JY; Delavenne, X; Deygas, B; Fontenay, M; Laporte, S; Mismetti, P; Nguyen, P; Zufferey, P, 2010) | 0.92 |
| " Detailed pharmacokinetic analyses were performed." | ( FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age. Barbour, A; Khanna, R; Nugent, DJ; O'Brien, SH; Yee, DL; Young, G, 2011) | 0.61 |
| " The monodisperse, (~50 nm), positively charged Fp-cLNCs with high drug loadings demonstrated linear pharmacokinetic profiles of the drug with an increased oral absolute bioavailability (up to ~21%) compatible with therapeutic anticoagulant effect (>0." | ( Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study. Benoit, JP; Lagarce, F; Legras, P; Macchi, L; Ramadan, A; Saulnier, P; Tessier-Marteau, A; Thomas, O, 2011) | 0.88 |
| " The bulk of clinical experience with paediatric anticoagulation rests with the first three of these agents, each of which requires higher bodyweight-based dosing for the youngest patients, compared with adults, in order to achieve comparable pharmacodynamic effects, likely related to an inverse correlation between age and bodyweight-normalized clearance of these drugs." | ( Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients. O'Brien, SH; Yee, DL; Young, G, 2013) | 0.39 |
| " Multivariate analysis and population pharmacokinetic analysis were performed to detect factors that necessitated withdrawal of fondaparinux and individual differences in its pharmacokinetics." | ( Population pharmacokinetics and pharmacodynamics of fondaparinux in Japanese patients after artificial total knee replacement
. Hanada, K; Iwa, K; Matsubara, H; Matsuo, T; Shibata, S; Takahashi, H; Takashima, Y; Tsukimura, Y, 2018) | 0.94 |
| " Population pharmacokinetic analysis demonstrated that individual renal function and body weight were significant factors associated with apparent clearance and volume of distribution, respectively." | ( Population pharmacokinetics and pharmacodynamics of fondaparinux in Japanese patients after artificial total knee replacement
. Hanada, K; Iwa, K; Matsubara, H; Matsuo, T; Shibata, S; Takahashi, H; Takashima, Y; Tsukimura, Y, 2018) | 0.73 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "To explore the efficacy and safety of fondaparinux combined with tirofiban in patients with high risk unstable angina (UA) undergoing complex percutaneous coronary intervention (PCI) ." | ( [The clinical efficacy and safety of fondaparinux combined with tirofiban hydrochloride in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention]. Chen, Y; Gao, CY; Li, MW; Rao, LX; Zhao, XM; Zhu, ZY, 2013) | 0.93 |
Fondaparinux is an ideal alternative in conditions where oral anticoagulants are not approved for use or in patients intolerant to low molecular weight heparins (LMWH) The study was to evaluate vasopressor effect on the bioavailability of subcutaneously administered fondaparinUX.
| Excerpt | Reference | Relevance |
|---|---|---|
| " There is nearly complete bioavailability by the sc." | ( Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Bick, RL; Fareed, J; Frapaise, FX; Jeske, WP; Samama, MM; Walenga, JM, 2002) | 1.76 |
| " Fondaparinux exhibits complete bioavailability by the subcutaneous route and is rapidly absorbed, reaching its maximum concentration approximately 2 h post dosing." | ( Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors. Bauer, KA; Hawkins, DW; Herbert, JM; Meuleman, DG; Peters, PC; Petitou, M; van Boeckel, CA, 2002) | 2.67 |
| " Based on studies of the heparin binding site of antithrombin, this novel pentasaccharide has superior pharmacokinetics and bioavailability when compared with LMWH and can be administered once daily." | ( Treatment of symptomatic venous thromboembolism: improving outcomes. Büller, HR, 2002) | 0.31 |
| " The drug replicates the sulphated antithrombin-binding pentasaccharide sequence in heparin and induces potent and specific antithrombin-mediated anti-Xa activity with excellent bioavailability and a long circulating half-life of 18 hours that makes it ideal for once-daily subcutaneous dosing." | ( Heparin pentasaccharide. Coghlan, DW; Gallus, AS, 2002) | 0.31 |
| " Fondaparinux exhibits a high bioavailability and is convenient to use as it only needs to be given once daily by subcutaneous injection." | ( Fondaparinux (Arixtra): a new anticoagulant. Giangrande, PL, 2002) | 2.67 |
| " Phase I trials have shown a 100% bioavailability after subcutaneous (s." | ( Fondaparinux sodium. Reverter, JC, 2002) | 1.76 |
| " Fondaparinux has nearly complete bioavailability after subcutaneous injection." | ( Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Gerotziafas, GT; Samama, MM, 2003) | 1.45 |
| " Inogatran and melagatran have a low bioavailability when given orally, whereas the chemically modified prodrug ximelagatran has a higher bioavailability." | ( Novel antithrombotic agents: indirect synthetic inhibitors of factor Xa and direct thrombin inhibitors. Evidences from clinical studies. De Stefano, V; Leone, AM; Leone, G; Rossi, E, 2004) | 0.32 |
| " The drugs are marked by bioavailability approximating 100%, linear dose-dependent pharmacokinetic profile at subcutaneous injection; they do not undergo metabolism and are excreted largely with urine." | ( [Prevention and treatment of venous thromboses and thromboembolism: pentasaccharides as novel anticoagulants selectively blocking Xe factor, their position and potential (data of the XIX International Congress on Thromboses and Hemostasis)]. Averkov, OV, 2004) | 0.32 |
| " Because of its excellent bioavailability after subcutaneous application once daily independent of body weight (within the range of 50-100 kg) monitoring of the substance is usually not necessary." | ( [Monitoring anticoagulation by fondaparinux: determination of anti factor Xa-level]. Dämgen-von Brevern, G; Kläffling, C; Lindhoff-Last, E, 2005) | 0.61 |
| " Synthetic, selective, and direct inhibitors to FXa, such as DX-9065a, are highly potent and orally bioavailable antithrombotic agents that have demonstrated an improved side effect profile, probably by allowing sufficient thrombin to remain for platelet activation and normal hemostasis, while preventing pathological thrombus formation." | ( Factor Xa inhibitors: new anti-thrombotic agents and their characteristics. Ieko, M; Koike, T; Naito, S; Nakabayashi, T; Tarumi, T; Yoshida, M, 2006) | 0.33 |
| " The complete bioavailability (100%) and elimination half-life of approximately 17 hours allows once-daily administration of fondaparinux." | ( Fondaparinux: use in thromboprophylaxis of acute medical patients. Dhillon, S; Plosker, GL, 2008) | 2 |
| " Fondaparinux has excellent bioavailability when administered subcutaneously, has a longer half-life than LMWHs, and is given once daily by subcutaneous injection in fixed doses, without anticoagulant monitoring." | ( Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Bauer, KA; Donati, MB; Gould, M; Hirsh, J; Samama, MM; Weitz, JI, 2008) | 1.26 |
| " However, common ICU conditions may impair the bioavailability of subcutaneously administered agents." | ( Bioavailability of fondaparinux to critically ill patients. Cumbo-Nacheli, G; Guzman, JA; Samavati, L, 2011) | 0.7 |
| "The purpose of the study was to evaluate vasopressor effect on the bioavailability of subcutaneously administered fondaparinux." | ( Bioavailability of fondaparinux to critically ill patients. Cumbo-Nacheli, G; Guzman, JA; Samavati, L, 2011) | 0.91 |
| "Vasopressor therapy does not appear to affect fondaparinux bioavailability or to reduce anti-factor Xa levels." | ( Bioavailability of fondaparinux to critically ill patients. Cumbo-Nacheli, G; Guzman, JA; Samavati, L, 2011) | 0.96 |
| " The monodisperse, (~50 nm), positively charged Fp-cLNCs with high drug loadings demonstrated linear pharmacokinetic profiles of the drug with an increased oral absolute bioavailability (up to ~21%) compatible with therapeutic anticoagulant effect (>0." | ( Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study. Benoit, JP; Lagarce, F; Legras, P; Macchi, L; Ramadan, A; Saulnier, P; Tessier-Marteau, A; Thomas, O, 2011) | 0.88 |
| " Fondaparinux exhibits complete bioavailability when administered subcutaneously, has a longer half-life than LMWHs, and is given once daily by subcutaneous injection in fixed doses, without coagulation monitoring." | ( Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Baglin, TP; Garcia, DA; Samama, MM; Weitz, JI, 2012) | 1.29 |
| " In contrast, lower estimates were obtained for volume of distribution and absorption rate constant parameters." | ( Thromboprophylaxis with fondaparinux in high-risk postoperative patients with renal insufficiency. Cohen-Wolkowiez, M; Fry, C; Gonzalez, D; Hester, W; Inman, BA; Ortel, TL, 2014) | 0.71 |
| " To overcome the low oral bioavailability of Fpx, a new nanoparticulate carrier has been developed." | ( Novel self assembling nanoparticles for the oral administration of fondaparinux: synthesis, characterization and in vivo evaluation. Bianchini, EP; Borgel, D; Bourgaux, C; Couvreur, P; Desmaële, D; Gref, R; Lepeltier, E; Pouget, T; Ralay-Ranaivo, B; Tranchant, JF, 2014) | 0.64 |
| " However, anticoagulants are poorly absorbed by oral route because of their high molecular weight, hydrophilicity and negative charges." | ( Trends in the development of oral anticoagulants. Borgel, D; Couvreur, P; Gref, R; Ralay-Ranaivo, B, 2015) | 0.42 |
| "Compared with older agents, low-molecular-weight heparins (LMWH) and fondaparinux offer improved bioavailability and more predictable, dose-independent clearance." | ( Laboratory Monitoring of Low-Molecular-Weight Heparin and Fondaparinux. Babin, JL; Traylor, KL; Witt, DM, 2017) | 0.93 |
| " As an anti-factor Xa drug, Fondaparinux has complete bioavailability subcutaneously, instant onset of action, a half-life of 15-20h, and a direct renal excretion without any metabolism." | ( The clinical use of Fondaparinux: A synthetic heparin pentasaccharide. Pan, N; Tan, L; Zhang, L; Zhang, M; Zhang, Y, 2019) | 1.13 |
| " Some of the advantages with fondaparinux are its chemical nature of synthesis, minimal risk of contamination, 100% absolute bioavailability subcutaneously, instant onset of action, a long half-life, direct renal excretion, fewer adverse reactions when compared with direct oral anticoagulants, and being an ideal alternative in conditions where oral anticoagulants are not approved for use or in patients intolerant to low molecular weight heparins (LMWH)." | ( Fondaparinux Sodium: Recent Advances in the Management of Thrombosis. Bauersachs, RM, ) | 1.87 |
Fondaparinux can be administered safely and efficaciously in a wide variety of patient populations, without the need for dosage modification. We evaluated anti-factor Xa levels in critically ill patients with SRD who were receiving an extended interval dosing regimen of fondaparinUX for VTE prophylaxis.
| Excerpt | Relevance | Reference |
|---|---|---|
| " (14 - 20 h) dosing regimens and no metabolism preceding renal excretion." | ( Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Bick, RL; Fareed, J; Frapaise, FX; Jeske, WP; Samama, MM; Walenga, JM, 2002) | 1.76 |
| " Thus, with the present dosing regimens, fondaparinux is probably preferable to enoxaparin for the prevention of venous thromboembolism." | ( Fondaparinux versus enoxaparin for the prevention of venous thromboembolism. Doggrell, SA, 2002) | 2.02 |
| " In humans, its pharmacokinetic profile is favorable, with a rapid onset of antithrombotic activity and an elimination half-life allowing a convenient once-daily dosing regimen." | ( The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa. Bouthier, J; Branellec, JF; Cariou, R; Donat, F; Duc, G; Duchaussoy, P; El Hajji, M; Garrigou, E; Herbert, JM; Necciari, J; Petitou, M, 2002) | 0.6 |
| " Peak plasma levels are achieved within two hours of dosing and the plasma half-life of fondaparinux is approximately 17 hours." | ( Fondaparinux (Arixtra): a new anticoagulant. Giangrande, PL, 2002) | 1.98 |
| " Its favorable pharmacokinetic profile and pharmacodynamics allow for safe and effective once-daily dosing in the majority of populations." | ( Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis. Bauer, KA, 2002) | 1.76 |
| " One feature of fondaparinux is that it can be administered safely and efficaciously in a wide variety of patient populations, without the need for dosage modification." | ( Use of selective factor Xa inhibitors in special populations. Turpie, AG, 2002) | 0.66 |
| " The elimination half-life is about 17 h and it is dose-independent, which allows a convenient once-daily dosing regimen." | ( Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Gerotziafas, GT; Samama, MM, 2003) | 0.54 |
| " Fondaparinux should further simplify the treatment of this frequent disease since a single once-daily fixed dosage regimen may effectively and safely treat both DVT and PE, an important point especially considering the frequent though clinically silent concomitance of these two thrombotic events." | ( Current perspectives on the treatment of venous thromboembolism: need for effective, safe and convenient new antithrombotic drugs. O'Shaughnessy, DF, 2004) | 1.23 |
| " Incremental cost calculations demonstrate that enoxaparin offers advantages over fondaparinux when dosed for 7 days postoperatively in this patient population." | ( Cost analysis of fondaparinux versus enoxaparin as venous thromboembolism prophylaxis in hip fracture surgery. Leslie, RB; Spruill, WJ; Wade, WE, ) | 0.7 |
| " Both are effective anticoagulants, but their use is associated with a number of impediments, including the need for intensive coagulation monitoring, wide variation in dose-response relationships, multiple drug interactions (in the case of warfarin), and serious immune-mediated thrombocytopenia (in the case of heparin)." | ( Limitations of traditional anticoagulants. Hawkins, D, 2004) | 0.32 |
| " The best dosing regimen and optimal timing of first dose for melagatran and ximelagatran remain to be determined, as do the mechanism and impact of drug disturbance of hepatic function." | ( Advances in anticoagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery. Andersen, JC, 2004) | 0.32 |
| " The elimination half-life of pentasaccharide is about 17 h, which allows a convenient once-daily dosing regime." | ( [New anticoagulants in clinical practice]. Boda, Z, 2004) | 0.32 |
| " Otherwise, they have some important limitations (narrow therapeutic window, highly variable dose-response relationship; limitation by the need of parenteral administration for heparins and the risk of heparin-induced thrombocytopenia) which provide opportunities for new antithrombotic drugs." | ( [Prophylaxis and treatment of venous thromboembolism: the role of new antithrombotic drugs]. Falciani, M; Imberti, D; Prisco, D, 2005) | 0.33 |
| " Both UFH and LMWH undergo pharmacokinetic changes during pregnancy, which sometimes necessitates dosage adjustments." | ( Minimising the risk of heparin-induced osteoporosis during pregnancy. Evans, J; Hawkins, D, 2005) | 0.33 |
| " Although both UFH and LMWH have received grade 1A recommendations for the prevention of VTE in at-risk medical patients in the 2004 American College of Chest Physicians consensus conference statements, LMWH has advantages over UFH in its once-daily dosing scheme, reduced incidence of major and minor bleeding events, and reduced incidence of heparin-induced thrombocytopenia." | ( Emerging strategies in the prevention of venous thromboembolism in hospitalized medical patients. Spyropoulos, AC, 2005) | 0.33 |
| " Warfarin, on the other hand, can be administered orally but requires the infrastructure for careful patient monitoring and dose adjustments because of its unpredictable dose-response relationship." | ( Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery. Colwell, C; Mouret, P, 2005) | 0.33 |
| " Warfarin has an unpredictable pharmacokinetic profile and a variable dose-response relationship that requires frequent coagulation monitoring and dose adjustments to maintain a target intensity that is both safe and effective." | ( Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention. Bounameaux, H; Huisman, MV, 2005) | 0.33 |
| " Low-molecular-weight heparins, available in the last 20 years, are manufactured from unfractionated heparin and have superior dose-response relationships because of fewer nonspecific reactions with plasma proteins and cells." | ( Heparin and other rapidly acting anticoagulants. Hyers, TM, 2005) | 0.33 |
| " Pharmacokinetic studies determined optimal dosing for clinically relevant anticoagulant levels in mice." | ( Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity. Choi, SH; Stevenson, JL; Varki, A, 2005) | 0.33 |
| " Unfractionated heparin can be used in most patients but difficulties with dosing and monitoring often lead to inadequate anticoagulation." | ( Heparins, low-molecular-weight heparins, and pentasaccharides. Ansell, JE; Dinwoodey, DL, 2006) | 0.33 |
| " Flexible dosing may reduce bleeding risk and allow easier use by starting the morning after surgery instead of staggered hours on the surgery day." | ( Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery. Colwell, CW; Davidson, BL; Kwong, LM; Turpie, AG, 2006) | 0.62 |
| " Both are effective anticoagulants, but their use is associated with a number of impediments, including the need for intensive coagulation monitoring, wide variation in dose-response relationships, multiple drug interactions (in the case of warfarin), and serious immune-mediated thrombocytopenia (in the case of heparin)." | ( Role of current and emerging antithrombotics in thrombosis and cancer. Mousa, SA, 2006) | 0.33 |
| "There remains considerable controversy regarding optimal initial warfarin dosing in patients with acute venous thromboembolism." | ( Comparison of a single end point to determine optimal initial warfarin dosing (5 mg versus 10 mg) for venous thromboembolism. DeSantis, SM; Gerhard-Herman, M; Goldhaber, SZ; Kosowsky, JM; Kucher, N; McKean, SC; Quiroz, R, 2006) | 0.33 |
| " We sought to determine if fondaparinux offered financial advantages over low-molecular weight heparin since it is given as a fixed dose over a wide range of patient weights rather then dosed directly on weight and because fondaparinux is not associated with heparin-induced thrombocytopenia (HIT)." | ( Minimizing costs for treating deep vein thrombosis: the role for fondaparinux. Jackson, WL; Moores, LK; Shorr, AF; Warkentin, TE, 2007) | 0.87 |
| " Patients at moderate thrombotic risk face a 10 to 20% risk of deep vein thrombosis (DVT) and require prophylaxis with low-dose unfractionated heparin or low molecular weight heparins (LMWHs) at a dosage < 3400 U once daily, or with graduated elastic stockings if their bleeding risk is high." | ( Prevention of venous thromboembolism. Pini, M; Spyropoulos, AC, 2006) | 0.33 |
| " Dose-response effects were observed in both studies; however, no statistically significant differences in major bleeding events were found among any groups." | ( Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients. Fuji, T; Fujita, S; Ochi, T, 2008) | 1.79 |
| " Fixed doses of LMWH are customarily used for VTE prophylaxis regardless of body weight or body mass index, but weight-based dosing with larger doses for obese patients may be more effective than fixed doses." | ( Assessing, preventing, and treating venous thromboembolism: evidence-based approaches. Nutescu, EA, 2007) | 0.34 |
| " Careful attention to dosing and excellent vascular access site management after cardiac catheterization are required to decrease the risk of bleeding and blood transfusion, which have been associated with increased mortality risk." | ( New anticoagulant options for ST-elevation myocardial infarction and unstable angina pectoris/non-ST-elevation myocardial infarction. Bates, ER, 2007) | 0.34 |
| " This reference therapeutic strategy is firstly parenteral and based on low-molecular-weight heparins (LMWH) or fondaparinux, subcutaneously prescribed at fixed dosage based on body weight without any systematic dose adjustment on hemostasis tests." | ( [Initial treatment of venous thromboembolic events]. Decousus, H; Mismetti, P; Moulin, N, 2007) | 0.55 |
| " Fondaparinux is also characterized by a simple dosing regimen, no need for coagulation monitoring, and potentially a lower risk of HIT compared with LMWH." | ( The pharmacoeconomics of deep vein thrombosis treatment. Shorr, AF, 2007) | 1.25 |
| " DTIs have antiplatelet effects, anticoagulant action, and most do not bind to plasma proteins, thereby providing a more consistent dose-response effect than UFH." | ( Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors. Lepor, NE, 2007) | 0.34 |
| "In a retrospective review of 10 patients with known or suspected HIT over a two-year period, medical records were evaluated for baseline laboratory results, treatment selection, initial dosing and monitoring, discontinuation of heparin, and alternative therapies chosen." | ( Standardizing the management of heparin-induced thrombocytopenia. Chiappe, J; Fugate, S, 2008) | 0.35 |
| " It is recommended that the clinician carefully evaluate the elderly patient's creatinine clearance and weight before prescribing anticoagulants, particularly when using fixed dosing regimens." | ( Prevention of venous thromboembolism in the geriatric patient. Brotman, DJ; Jaffer, AK, 2008) | 0.35 |
| " New anticoagulants have been developed that selectively inhibit thrombin or factor Xa, and have predictable dose-response relationships." | ( New anticoagulants. Bauer, KA, 2008) | 0.35 |
| " An almost linear dose-response and high sensitivity of the assay for unfractionated heparin (UFH), low-molecular-weight heparins (LMWHs), r-hirudin, and argatroban was found." | ( Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors. Calatzis, A; Haas, S; Peetz, D; Rudin, K; Spannagl, M; Wilmer, M, 2008) | 0.55 |
| " Low-molecular-weight heparins (LMWH) are the preferred class of drugs due to multiple advantages, including daily dosing and a decreased risk of heparin-induced thrombocytopenia, to name a few." | ( Prevention of venous thromboembolism in hospitalized medical patients. Jaffer, AK; Lenchus, JD, 2008) | 0.35 |
| " This dosage regimen showed a favorable efficacy/safety clinical profile and should be appropriate in preventing venous thromboembolism in patients with moderate renal impairment." | ( Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients. Boyle, DA; Fuji, T; Lensing, AW; Turpie, AG, 2009) | 0.6 |
| " Addition of antithrombin concentrates results in a shift of the dose-response curve." | ( The reduced anticoagulant effect of fondaparinux at low antithrombin levels. Ahmad-Nejad, P; Borggrefe, M; Dempfle, CE; Eichner, J; Neumaier, M; Suvajac, N, 2009) | 0.63 |
| " Serum levels indicated adequate absorption of the drug and an effective dosing regimen." | ( Fondaparinux for prevention of venous thromboembolism in high-risk trauma patients: a pilot study. Atkinson, K; Bir, N; Kallet, R; Knudson, MM; Lu, JP, 2009) | 1.8 |
| " Its once-daily dosing regimen can improve compliance and reduce cost and eliminate risk of heparin-induced thrombocytopenia." | ( Fondaparinux for prevention of venous thromboembolism in high-risk trauma patients: a pilot study. Atkinson, K; Bir, N; Kallet, R; Knudson, MM; Lu, JP, 2009) | 1.8 |
| " All LMWHs tested, as well as fondaparinux, display a similar dose-response in Heptest compared to the chromogenic anti-factor Xa assay." | ( Heptest-STAT, a new assay for monitoring of low-molecular-weight heparins, is not influenced by pregnancy-related changes of blood plasma. Ahmad-Nejad, P; Borggrefe, M; Dempfle, CE; Elmas, E; Neumaier, M; Zharkowa, U, 2009) | 0.64 |
| " The optimal drug therapies and dosing strategies for reducing VTE risk are not well defined for many clinical situations, despite the availability of evidence-based guidelines from authoritative sources." | ( Issues in assessing and reducing the risk for venous thromboembolism. Dager, WE, 2010) | 0.36 |
| " Dosing strategies for medications used in the ICU are typically developed for use in noncritically ill patients and, therefore, do not account for the altered pharmacokinetic and pharmacodynamic properties encountered in the critically ill as well as the increased potential for drug-drug interactions, given the far greater number of medications ordered." | ( Adverse drug events associated with disorders of coagulation. Barletta, JF; Cooper, B; Ohlinger, MJ, 2010) | 0.36 |
| " Additional concerns refer to the dosing-regimens and their practical administration: Fondaparinux, rivaroxaban and dabigatran are dosed to achieve maximum effects very close to their limits of tolerance whereas wide dosing spectra for the low molecular weight herparin (LMWH)'s indicate the potential for dose adaptation and increase." | ( Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux. Fareed, J; Hull, R; Welzel, D, 2011) | 0.8 |
| " Clinicians are increasingly being challenged with making uncertain anticoagulant dosing decisions, as the optimal dosing strategy for most anticoagulants in the obese patient population remains unknown." | ( Anticoagulating obese patients in the modern era. Arya, R; Patel, JP; Roberts, LN, 2011) | 0.37 |
| "The administration of low-molecular-weight heparins to obese patients (body mass index [BMI] of ≥30 kg/m(2)) at the dose recommended for VTE prophylaxis has been reported to result in increased thromboembolic events and decreased anti-factor Xa levels, and some evidence indicates that weight-based dosing adjustments may be appropriate." | ( Effect of fondaparinux prophylaxis on anti-factor Xa concentrations in patients with morbid obesity. Borrego, M; Burnett, A; Garcia, D; Martinez, L; Streeter, JC; Townsend, K, 2011) | 0.77 |
| " Because dabigatran is cleared principally by the kidneys, dosage adjustments are required in the setting of renal dysfunction." | ( Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor. Augoustides, JG, 2011) | 0.37 |
| " Weak recommendations deal with such issues as loading doses, initiation overlap, monitoring frequency, vitamin K supplementation, patient self-management, weight and renal function adjustment of doses, dosing decision support, drug interactions to avoid, and prevention and management of bleeding complications." | ( Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Crowther, M; Fish, J; Guyatt, GH; Holbrook, A; Kovacs, MJ; Schulman, S; Svensson, PJ; Vandvik, PO; Veenstra, DL; Witt, DM, 2012) | 0.38 |
| " As the drug is mainly eliminated by the kidneys, a reduced dosage (1." | ( Pharmacokinetics of fondaparinux 1.5 mg once daily in a real-world cohort of patients with renal impairment undergoing major orthopaedic surgery. Bazzoli, C; Delavenne, X; Laporte, S; Mismetti, P; Nguyen, P; Rosencher, N; Samama, CM; Zufferey, P, 2012) | 0.7 |
| "We studied the pharmacokinetics (PK) of this dosage regimen using data from a real-world cohort of 442 patients with renal impairment (creatinine clearance 20-50 ml/min) undergoing MOS." | ( Pharmacokinetics of fondaparinux 1.5 mg once daily in a real-world cohort of patients with renal impairment undergoing major orthopaedic surgery. Bazzoli, C; Delavenne, X; Laporte, S; Mismetti, P; Nguyen, P; Rosencher, N; Samama, CM; Zufferey, P, 2012) | 0.7 |
| "5 mg reduced dosage regimen of fondaparinux available for this context." | ( Venous thromboembolism prevention with fondaparinux 1.5 mg in renally impaired patients undergoing major orthopaedic surgery. A real-world, prospective, multicentre, cohort study. Deygas, B; Laporte, S; Mismetti, P; Nguyen, P; Presles, E; Rosencher, N; Samama, CM; Vielpeau, C, 2012) | 0.93 |
| " Thrombotic storm was defined as newly diagnosed multisite venous thromboembolism (VTE) with acute thrombus progression despite conventional or higher than conventional dosing of heparin or low molecular weight heparin." | ( Treatment, survival, and thromboembolic outcomes of thrombotic storm in children. Gibson, E; Goldenberg, NA; Knoll, CM; Manco-Johnson, MJ; Mourani, PM; Soep, J; Wang, M, 2012) | 0.38 |
| " This review focuses on pharmacologic information relevant to the dosing of unfractionated heparin, low molecular weight heparin, warfarin, bivalirudin, argatroban and fondaparinux in paediatric patients." | ( Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients. O'Brien, SH; Yee, DL; Young, G, 2013) | 0.58 |
| " On the basis of dose-response curves, we identified low and moderate doses of EP217609 resulting in similar ex vivo prolongation of the APTT as α-NAPAP analog and comparable ex vivo anti-FXa activity as fondaparinux." | ( EP217609, a neutralisable dual-action FIIa/FXa anticoagulant, with antithrombotic effects in arterial thrombosis. Alame, G; Freund, M; Gachet, C; Hechler, B; Magnenat, S; Mangin, PH; Petitou, M; Riehl, N, 2015) | 0.6 |
| " Data regarding dosing and anti-Xa monitoring are lacking in this population." | ( Clinical experience with prophylactic fondaparinux in critically ill patients with moderate to severe renal impairment or renal failure requiring renal replacement therapy. An, G; Antigua, A; Bushwitz, J; Cope, J; Patel, A; Zumberg, M, 2015) | 0.69 |
| " Fondaparinux dose, dosing frequency, and anti-Xa level monitoring are described." | ( Clinical experience with prophylactic fondaparinux in critically ill patients with moderate to severe renal impairment or renal failure requiring renal replacement therapy. An, G; Antigua, A; Bushwitz, J; Cope, J; Patel, A; Zumberg, M, 2015) | 1.6 |
| "Empirical dose adjustments may be prudent in critically ill patients with renal dysfunction; however, the optimal fondaparinux dosage in this population remains unknown." | ( Clinical experience with prophylactic fondaparinux in critically ill patients with moderate to severe renal impairment or renal failure requiring renal replacement therapy. An, G; Antigua, A; Bushwitz, J; Cope, J; Patel, A; Zumberg, M, 2015) | 0.9 |
| " However, there is disagreement regarding the optimal dosing and duration of anticoagulant therapy." | ( The EFFORT trial: Preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Beselman, A; Canner, J; Chen, J; Lidor, A; Magnuson, T; Prokopowicz, G; Schweitzer, M; Steele, KE; Streiff, M; Verde, F; Wyse, R, ) | 0.37 |
| "Activated clotting time (ACT) is widely used to guide unfractionated heparin dosing during percutaneous coronary intervention." | ( Activated clotting time and outcomes during percutaneous coronary intervention for non-ST-segment-elevation myocardial infarction: insights from the FUTURA/OASIS-8 Trial. Ducrocq, G; Gao, P; Jolly, S; Mehta, SR; Moreno, R; Patel, T; Rao, SV; Steg, PG, 2015) | 0.42 |
| " Low-molecular weight heparins, heparin, and fondaparinux are commonly used agents to prevent VTE, each of which has well established dosing regimens in patients with normal body mass index." | ( Chemical prophylaxis to prevent venous thromboembolism in morbid obesity: literature review and dosing recommendations. Lalama, JT; Ritz, LI; Vandiver, JW, 2016) | 0.69 |
| " The increased incidence of major bleeding (excluding fatal) due to fondaparinux could be perhaps lowered by dosage reduction in patients with a mildly decreased creatinine clearance." | ( [Contribution of novel anticoagulants fondaparinux and dabigatran to venous thromboembolism prevention]. Antonijević, N; Apostolović, M; Jovanović, L; Kanjuh, V; Vukčević, M; Živković, I, ) | 0.64 |
| " These NCCN Guidelines Insights summarize the data supporting new dosing recommendations for VTE prophylaxis in obese patients with cancer." | ( Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. Ashrani, A; Bockenstedt, PL; Chesney, C; Eby, C; Engh, AM; Fanikos, J; Fenninger, RB; Fogerty, AE; Gao, S; Goldhaber, SZ; Hendrie, P; Holmstrom, B; Kuderer, N; Lee, A; Lee, JT; Lovrincevic, M; McMillian, N; Millenson, MM; Neff, AT; Ortel, TL; Paschal, R; Shattil, S; Siddiqi, T; Smock, KJ; Soff, G; Streiff, MB; Wang, TF; Yee, GC; Zakarija, A, 2015) | 0.42 |
| "A central challenge in designing and administering effective anticoagulants is achieving the proper therapeutic window and dosage for each patient." | ( A novel, rapid method to compare the therapeutic windows of oral anticoagulants using the Hill coefficient. Chang, JB; Karan, C; Quinnies, KM; Rand, JH; Realubit, R; Tatonetti, NP, 2016) | 0.43 |
| "Compared to enoxaparin (most commonly dosed 40 mg once daily), the relative risk (RR) of VTE was lowest for edoxaban 30 mg once daily (0." | ( Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis. Gage, BF; Ganti, BR; Lee, ED; Lin, H; Nunley, RM; Venker, BT, 2017) | 0.46 |
| " We evaluated anti-factor Xa levels in critically ill patients with SRD who were receiving an extended interval dosing regimen of fondaparinux for VTE prophylaxis." | ( Assessment of an Extended Interval Fondaparinux Dosing Regimen for Venous Thromboembolism Prophylaxis in Critically Ill Patients with Severe Renal Dysfunction Using Antifactor Xa Levels. Riley, LK; Tennenberg, SD; Wahby, KA, 2017) | 0.94 |
| " As an alternative to inconvenient and expensive injections of fondaparinux, personalized dosing of a direct oral anticoagulant was sought using clinical pharmacology techniques." | ( Personalized Anticoagulation: Guided Apixaban Dose Adjustment to Compensate for Pharmacokinetic Abnormalities Related to Short-Bowel Syndrome. Kim, RB; Pollak, PT; Sun, GR, 2018) | 0.72 |
| " We performed daily assessment of antithrombin- and fondaparinux-specific anti-Xa levels in a 50-year-old female of unknown ethnicity to ensure that fondaparinux dosing was maintained within an acceptable range." | ( Monitoring Fondaparinux in the Setting of Antithrombin Deficiency. Feldman, AZ; Pham, HP; Simmons, SC; Staley, EM; Williams, LA, 2019) | 1.15 |
| " We describe a patient diagnosed with anti-phospholipase A2 receptor antibody positive membranous nephropathy and recurrent VTE while on therapeutic dosing of apixaban." | ( Recurrent venous thromboembolism in primary membranous nephropathy despite direct Xa inhibitor therapy. Crona, DJ; Derebail, VK; Mooberry, MJ; Nachman, PH; Reynolds, ML, 2019) | 0.51 |
| "This study demonstrates the stable long-term pediatric dosing of fondaparinux with similar efficacy and safety when compared to other anticoagulants." | ( FondaKIDS III: A long-term retrospective cohort study of fondaparinux for treatment of venous thromboembolism in children. Shen, X; Wile, R; Young, G, 2020) | 1.04 |
| " Given the favourable safety profile of NOACs (especially if a reduced dosage of Apixaban or Rivaroxaban is initiated after at least six months of therapeutic anticoagulation), extended oral anticoagulation of indefinite duration should be considered for all patients with intermediate risk of recurrence." | ( [Antithrombotic Treatment of Pulmonary Embolism]. Ebner, M; Lankeit, M, 2020) | 0.56 |
| "Pediatric patients with obesity may benefit from proactively adjusting enoxaparin dosing on initiation of therapy." | ( Low-Molecular-Weight Heparin and Fondaparinux Use in Pediatric Patients With Obesity. Fenn, NE; Garner, MP; Onuoha, CP, 2021) | 0.9 |
| " Patients were treated with LMWH or FPX at therapeutic dosage and reduction was considered in selected cases." | ( Comparison of Fondaparinux and Low-Molecular-Weight Heparin in the Treatment of Portal Vein Thrombosis in Cirrhosis. Angeli, P; Bombonato, G; Burra, P; Piano, S; Sacerdoti, D; Senzolo, M; Shalaby, S; Simioni, P; Tonello, S; Tonon, M; Zanetto, A, 2021) | 0.98 |
| " This study characterizes the pharmacokinetics (PK) and pharmacodynamics (PD) of fondaparinux in DD-CKD patients undergoing renal replacement therapy (RRT), to assess dosing strategies." | ( Population pharmacokinetics-pharmacodynamics of fondaparinux in dialysis-dependent chronic kidney disease patients undergoing chronic renal replacement therapy. Bednářová, V; Hartinger, JM; Hladinová, Z; Krekels, EHJ; Matthios, A; Michaličková, D; Polakovič, V; Slanař, O; Szonowská, B; Tesař, V, 2022) | 1.2 |
| "Model-based simulations showed that standard dosing (2." | ( Population pharmacokinetics-pharmacodynamics of fondaparinux in dialysis-dependent chronic kidney disease patients undergoing chronic renal replacement therapy. Bednářová, V; Hartinger, JM; Hladinová, Z; Krekels, EHJ; Matthios, A; Michaličková, D; Polakovič, V; Slanař, O; Szonowská, B; Tesař, V, 2022) | 0.98 |
| " He was treated with azithromycin, isoprinosine, lopinavir, and fondaparinux with thromboprophylaxis dosage since admission." | ( The Challenging Anticoagulant Therapy in COVID19 Patient with Associated Coagulopathy. Airlangga, MP; Fatimah, FN; Miftahussurur, M; Pradana, AD; Rianda, RA; Rianda, RV; Subkhan, M, 2021) | 0.86 |
| " We recommend research to refine VTE risk stratification, and to establish the optimal dosing and duration of thromboprophylaxis." | ( Thromboprophylaxis for venous thromboembolism prevention in hospitalized patients with cirrhosis: Guidance from the SSC of the ISTH. Hernandez-Gea, V; Lisman, T; Magnusson, M; Roberts, LN; Stanworth, S; Thachil, J; Tripodi, A, 2022) | 0.72 |
| Role | Description |
|---|---|
| anticoagulant | An agent that prevents blood clotting. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| amino sugar | Any sugar having one or more alcoholic hydroxy groups replaced by substituted or unsubstituted amino groups. |
| oligosaccharide sulfate | Any carbohydrate sulfate that is an oligosaccharide carrying at least one O-sulfo substituent. |
| pentasaccharide derivative | An oligosaccharide derivative that is formally obtained from a pentasaccharide. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Coagulation factor X | Homo sapiens (human) | IC50 (µMol) | 0.0110 | 0.0003 | 0.5937 | 10.0000 | AID1548117 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| proteolysis | Coagulation factor X | Homo sapiens (human) |
| blood coagulation | Coagulation factor X | Homo sapiens (human) |
| positive regulation of cell migration | Coagulation factor X | Homo sapiens (human) |
| positive regulation of TOR signaling | Coagulation factor X | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| serine-type endopeptidase activity | Coagulation factor X | Homo sapiens (human) |
| calcium ion binding | Coagulation factor X | Homo sapiens (human) |
| protein binding | Coagulation factor X | Homo sapiens (human) |
| phospholipid binding | Coagulation factor X | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular region | Coagulation factor X | Homo sapiens (human) |
| endoplasmic reticulum lumen | Coagulation factor X | Homo sapiens (human) |
| Golgi lumen | Coagulation factor X | Homo sapiens (human) |
| plasma membrane | Coagulation factor X | Homo sapiens (human) |
| external side of plasma membrane | Coagulation factor X | Homo sapiens (human) |
| extracellular space | Coagulation factor X | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1346098 | Human serpin family C member 1 (Blood coagulation components) | 2002 | Clinical pharmacokinetics, , Volume: 41 Suppl 2 | Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. |
| AID1548117 | Inhibition of coagulation factor 10a (unknown origin) incubated for 2 mins in presence of AT3 by chromogenic substrate based fluorescence assay | 2020 | Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8 | Modulating Heparanase Activity: Tuning Sulfation Pattern and Glycosidic Linkage of Oligosaccharides. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 500 (43.71) | 29.6817 |
| 2010's | 545 (47.64) | 24.3611 |
| 2020's | 99 (8.65) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (82.97) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 112 (9.41%) | 5.53% |
| Reviews | 355 (29.83%) | 6.00% |
| Case Studies | 146 (12.27%) | 4.05% |
| Observational | 24 (2.02%) | 0.25% |
| Other | 553 (46.47%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery [NCT01267305] | 362 participants (Actual) | Interventional | 2011-01-31 | Completed | |||
| Women's Cancer Center Protocol #45: Prolonged Venous Thromboembolism Prophylaxis With Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial [NCT00381888] | Phase 2 | 44 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction [NCT01121770] | Phase 1 | 9 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| Safety of Fondaparinux as Postpartum Venous Thromboembolism Prophylaxis [NCT04447378] | Phase 4 | 60 participants (Actual) | Interventional | 2017-09-01 | Completed | ||
| Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial) [NCT02744092] | 811 participants (Actual) | Interventional | 2016-12-13 | Completed | |||
| Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in the Treatment of Acute Pulmonary Thromboembolism (PE) [NCT00981409] | Phase 3 | 41 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia [NCT00603824] | Phase 4 | 0 participants (Actual) | Interventional | 2008-01-31 | Withdrawn(stopped due to PI relocated) | ||
| An International, Multicentre, Randomised, Open, Controlled, Two-parallel Group, Phase II Pilot Study to Evaluate the Efficacy and Safety of ARIXTRA™ for Anticoagulation of Patients With Atrial Fibrillation Undergoing Electric Cardioversion Following Tran [NCT00911300] | Phase 2 | 349 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| The Safety and Efficacy of Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism in Medical Patients With Renal Insufficiency [NCT00927602] | Phase 4 | 206 participants (Actual) | Interventional | 2009-04-30 | Terminated(stopped due to study was stopped after enrolment of about 200 patients for slow recruitment) | ||
| Xarelto® Regulatory Post-Marketing Surveillance [NCT01029743] | 3,388 participants (Actual) | Observational | 2009-12-31 | Completed | |||
| A Pilot Study to Determine the Feasibility of Conducting a Randomized Clinical Trial Comparing Fondaparinux Sodium (Arixtra) Once Daily With Enoxaparin (Lovenox®) Twice Daily With Respect to Preventing VTE After Bariatric Surgery in Obese Patients [NCT00894283] | Early Phase 1 | 198 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism After Elective Total Hip Replacement Surgery [NCT00320398] | Phase 3 | 114 participants (Actual) | Interventional | 2006-01-30 | Completed | ||
| 07-742 Phase I/ Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression [NCT00659399] | Phase 1 | 0 participants (Actual) | Interventional | 2008-01-31 | Withdrawn(stopped due to Low accrual) | ||
| A Multicentre, Randomized, Open-label Study to Evaluate the Efficacy andSafety of Fondaparinux Versus Low Molecular Weight Heparin(Nadroparin) in Patients Requiring Rigid or Semi-rigid Immobilization for at Least 21 Days and up to 45 Days Because of Isola [NCT00843492] | Phase 3 | 1,351 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| An International, Multicentre, Randomised, Double-blind, Placebo-controlled, Two-parallel Group, Phase III Study to Evaluate the Efficacy and Safety of ARIXTRA (2.5mg Subcutaneously) for the Treatment of Patients With Acute Symptomatic Isolated Superficia [NCT00443053] | Phase 3 | 3,002 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| FondaparinUx Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) (FUTURA). A Prospective Study Evaluating the Safety of Two Regimens of Adjunctive Intravenous UFH During PCI in High Risk Patients With Unstabl [NCT00790907] | Phase 4 | 3,235 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Prophylaxis Against Thromboembolic Disease Following Orthopaedic Surgeries on Extremities [NCT00767559] | 330 participants (Anticipated) | Interventional | 2008-11-30 | Active, not recruiting | |||
| Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal (Urology,Obstetrics,Gynecology) [NCT01390883] | 475 participants (Actual) | Observational | 2008-12-31 | Completed | |||
| Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal General Surgery [NCT01390896] | 329 participants (Actual) | Observational | 2009-09-30 | Completed | |||
| Evaluate (Post Approval) the Adherence to the Prescribing Information for ARIXTRA® (Fondaparinux) in ACS Patients- Commitment of the Fondaparinux EU-RMP [NCT01406301] | 1 participants (Actual) | Observational | 2008-03-31 | Completed | |||
| A Phase 3, Open-label, Randomized, Multi-center, Controlled Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of Edoxaban and to Compare the Efficacy and Safety of Edoxaban With Standard of Care Anticoagulant Therapy in Pediatric Subjects From B [NCT02798471] | Phase 3 | 290 participants (Actual) | Interventional | 2017-03-27 | Completed | ||
| Prophylaxis of Venous Thromboembolism in Patients With a Nonsurgical Fracture of the Lower Extremity Immobilised in a Below-Knee Plaster Cast [NCT00881088] | Phase 2/Phase 3 | 669 participants (Anticipated) | Interventional | 2009-04-30 | Recruiting | ||
| Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism After Hip Fracture Surgery [NCT00320424] | Phase 3 | 48 participants (Actual) | Interventional | 2006-02-16 | Completed | ||
| Switching From Arixtra (Fondaparinux) to Angiomax (Bivalirudin) or Unfractionated Heparin in Patients With Acute Coronary Syndromes (ACS) Without ST-segment Elevation Undergoing Percutaneous Coronary Intervention (PCI): SWITCH III [NCT00464087] | Phase 3 | 100 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Choice of the Optimal Method for Treatment of Acute Thrombophlebitis of the Varicose Great Saphenous Vein: Comparison of Endovenous Laser Ablation and Conservative Approach [NCT05001776] | Phase 4 | 105 participants (Actual) | Interventional | 2021-08-16 | Completed | ||
| Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in the Treatment of Acute Deep Vein Thrombosis (DVT) [NCT00911157] | Phase 3 | 39 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment [NCT01428531] | 200 participants (Actual) | Observational | 2012-01-31 | Completed | |||
| Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg) [NCT01428544] | 5 participants (Actual) | Observational | 2012-03-31 | Completed | |||
| Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux,in Venous Thromboembolic Events Prevention in Patients With Renal Impairment and Undergoing a Major Orthopaedic Surgery. PROPICE Study [NCT00555438] | Phase 4 | 451 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Randomized, Single Blind, Parallel Study to Compare the Safety and Efficacy of ARIXTRA to Enoxaparine in Patients Undergoing Elective Major Hip or Knee Replacement or a Revision of Components. [NCT00328939] | Phase 3 | 240 participants | Interventional | 2004-05-31 | Completed | ||
| Thromboprophylaxis in the Morbidly Obese With Weight Based Dosing of Fondaparinux: A Pharmacodynamic Study [NCT00346879] | Phase 1 | 0 participants (Actual) | Interventional | 2006-08-31 | Withdrawn(stopped due to Funding withdrawn; study closed due to lack of accrual.) | ||
| An International, Randomized, Double-blind Study Evaluating the Efficacy and Safety of Fondaparinux Versus Enoxaparin in the Acute Treatment of Unstable Angina/Non ST-segment Elevation MI Acute Coronary Syndromes [NCT00139815] | Phase 3 | 20,078 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Pharmacokinetics of Fondaparinux (Arixtra) to Critically Ill Patients on Vasopressor Therapy [NCT00424281] | 40 participants | Observational | 2007-02-28 | Not yet recruiting | |||
| A Pilot Dose-finding and Pharmacokinetic Study of Fondaparinux in Children With Deep Vein Thrombosis or Heparin-induced Thrombocytopenia [NCT00412464] | Phase 1 | 24 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Systematische Dokumentation Von Patienten Mit Akutem HIT-Verdacht [NCT01304238] | 195 participants (Actual) | Observational | 2009-02-28 | Completed | |||
| Pharmacokinetic Properties of Fondaparinux Sodium in Morbidly Obese Volunteers [NCT00436787] | Phase 2 | 21 participants (Anticipated) | Interventional | 2007-02-28 | Completed | ||
| Fondaparinux Compared With Heparin to Prevent Thrombotic Complications and Graft Failure in Patients Undergoing Coronary Artery Bypass Graft Surgery [NCT00474591] | Phase 3 | 100 participants (Anticipated) | Interventional | Not yet recruiting | |||
| Phase I Feasibility Study of the Combination of Fondaparinux (Arixtra) With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer [NCT00476216] | Phase 1 | 23 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| Studies of Fondaparinux in Patients With Renal Dysfunction: PK Study of Fondaparinux in Outpatients With Renal Dysfunction [NCT00483600] | 0 participants (Actual) | Interventional | 2007-08-31 | Withdrawn(stopped due to unable to enroll) | |||
| Arixtra(Fondaparinux) vs. Lovenox (Enoxaparin) in Prevention of DVT in Acute Medically Ill, Non-surgical Patients [NCT00521885] | 1 participants (Actual) | Interventional | 2007-09-30 | Terminated(stopped due to Study stopped due to lack of accrual) | |||
| A Multicenter, Randomized, Double-blind, Parallel Group Trial to Demonstrate the Efficacy of Fondaparinux Sodium in Association With Intermittent Pneumatic Compression (IPC) Versus IPC Used Alone for the Prevention of Venous Thromboembolic Events in Subje [NCT00038961] | Phase 3 | 1,309 participants (Actual) | Interventional | 2001-11-30 | Completed | ||
| Phase IV, Single Arm Study to Obtain Information Regarding the Safety and Efficacy of Fondaparinux Given Outpatient for Treatment of Acute Pulmonary Embolism [NCT00378027] | 0 participants (Actual) | Observational | 2006-08-31 | Withdrawn(stopped due to enrollment criteria not met by PI patient population) | |||
| An International Randomized Study Evaluating the Efficacy and Safety of Fondaparinux Versus Control Therapy in a Broad Range of Patients With ST Segment Elevation Acute Myocardial Infarction. [NCT00064428] | Phase 3 | 12,092 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| [NCT00060554] | Phase 2 | 300 participants | Interventional | 2003-04-30 | Withdrawn(stopped due to Drug sold to Sanofi-Aventis who sold it to GSK; OBS no longer owns study and does not have data.) | ||
| A Randomized Control Trial of Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With A Venous Thromboembolism [NCT00423683] | Phase 3 | 64 participants (Actual) | Interventional | 2007-01-31 | Terminated(stopped due to Study accrual stopped due to poor accrual.) | ||
| A Phase II Trial Using Fondaparinux in Patients With Confirmed or Suspected Heparin-Induced Thrombocytopenia (HIT) [NCT00673439] | Phase 2 | 3 participants (Actual) | Interventional | 2007-11-30 | Terminated(stopped due to study terminated due to low accrual) | ||
| Extended Deep Venous Thrombosis Prophylaxis in Gynecologic Oncology Surgery With Intermittent Compression Devices (ICD) With or Without Postoperative Arixtra (Fondaparinux Sodium): A Randomized Controlled Trial [NCT00539942] | Phase 3 | 7 participants (Actual) | Interventional | 2007-04-30 | Terminated(stopped due to Problems with accrual) | ||
| Thromboprophylaxis With Fondaparinux of Deep Vein Thrombosis and Pulmonary Embolism in the Acutely-ill Medical Inpatients With Thrombocytopenia [NCT01727401] | Phase 4 | 7 participants (Actual) | Interventional | 2012-11-30 | Terminated(stopped due to Slow recruitment rate) | ||
| Pilot Study Evaluating Alterations in Thrombogenicity and Platelet Reactivity Following Lower Extremity Arthroplasty [NCT01809054] | Phase 4 | 54 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| Fondaparinux as Monotherapy for Deep Vein Thrombosis and/or Pulmonary Embolism (Pilot Study) [NCT00413504] | 30 participants (Actual) | Interventional | 2006-04-30 | Completed | |||
| Assessment of the Safety and Efficacy of Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Renal Failure. [NCT00256100] | 20 participants (Actual) | Interventional | 2004-06-30 | Terminated(stopped due to Teh Priincipal investigator responsible for the trial no longer employed at the study site.) | |||
| Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism (VTE) After Abdominal Surgery [NCT00333021] | Phase 3 | 127 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| ARIXTRA® Physician Adherence to the Prescribing Information in Isolated Superficial Vein Thrombosis (SVT) Patients. [NCT01691495] | 1 participants (Actual) | Observational | 2012-10-31 | Completed | |||
| Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients [NCT01727427] | 695 participants (Actual) | Observational | 2012-11-30 | Completed | |||
| Superficial Vein Thrombosis (SVT) Treated for Forty-five Days With Rivaroxaban Versus Fondaparinux [NCT01499953] | Phase 3 | 472 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| Pilot Pharmacoeconomic Evaluation of Fondaparinux Treatment of Pulmonary Embolism (PE) Compared to Treatment With Unfractionated Heparin [NCT00377091] | Phase 4 | 0 participants (Actual) | Interventional | 2007-06-30 | Withdrawn(stopped due to Study pulled due to a grant disagreement between the U of M and SMDC) | ||
| Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery [NCT01444612] | 4,068 participants (Actual) | Observational | 2010-02-28 | Completed | |||
| Platelet Inhibition With GP IIb/IIIa Inhibitor in Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). A Compassionate Use Protocol [NCT04368377] | Phase 2 | 5 participants (Actual) | Interventional | 2020-04-06 | Completed | ||
| Retrospektive Studie zu Patientinnen, Die pränatal, Perinatal Oder Postnatal Prophylaktisch Oder Therapeutisch Mit Fondaparinux Behandelt Wurden [NCT01004939] | 120 participants (Actual) | Observational | 2010-03-31 | Completed | |||
| A Study of the Efficacy of Preventive Dosing of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism (VTE) in Patients Undergoing Coronary Bypass Surgery Receiving Routine Mechanical Prophylaxis [NCT00789399] | 78 participants (Actual) | Interventional | 2009-11-19 | Terminated(stopped due to Principal Investigator moved to another region of the country) | |||
| Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients: An Investigator Initiated Protocol [NCT00493896] | Phase 3 | 27 participants (Actual) | Interventional | 2007-07-31 | Terminated(stopped due to low enrollment) | ||
| The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients [NCT00531843] | Phase 2/Phase 3 | 105 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Use of Fondaparinux in Critically Ill Patients With Renal Failure [NCT01467583] | Phase 4 | 32 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Increased Risk of Venous Thromboembolism and Higher Hypercoagulable State in Patients Recovered in Intensive Care Unit and in Medical Ward for Coronavirus Disease 2019 (COVID-19) [NCT04359212] | 90 participants (Actual) | Observational | 2020-05-01 | Completed | |||
| Phase III Clinical Study of DU-176b (Venous Thromboembolism): Japanese, Multicenter, Open-label Study of DU-176b in Patients With Severe Renal Impairment (SRI) Undergoing Orthopedic Surgery of the Lower Limbs [NCT01857583] | Phase 3 | 80 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| The Effects of Arixtra on Wound Drainage Following Total Joint Arthroplasty [NCT00909064] | Phase 4 | 114 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Risk of Hemorrhage in Patients Prescribed Arixtra Compared to LMWH [NCT01064362] | 13,442 participants (Actual) | Observational | 2010-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||